Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure,

The program is initially being developed in combination with JANX007, with the goal of further enhan

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology

Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list.

Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform t

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh in

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks C

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analy

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy r

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the s

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates,

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks C

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While

Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runw

Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowe

Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs d

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biop

Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Unde

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, sign

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average ra

Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overwei

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t

Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analy

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JAN

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with cons

Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company

Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold

Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight

Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin

Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lo

Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers th

JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy a